Answers are grounded in this paper and cite their sources.
Evaluation of fecal calprotectin levels to detect bowel inflammation in spondyloarthritis patients, highlighting importance for diagnosis.
We greatly appreciate the interest and the comments made by Allen Pai and colleagues about our article: “Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis”. To clarify some issues raised by their letter, we would like to highlight some key points about our study's aims and its design. First, the study aimed to evaluate the utility of fecal calprotectin (fcal) in detecting endoscopic and microscopic bowel inflammation in patients with spondyloarthritis (SpA) but without a previous diagnosis of inflammatory bowel disease (IBD). The literature is extensive in demonstrating the important role of fcal in monitoring intestinal inflammation in patients with IBD.1 One of the main questions to be answered by our study was whether fcal could help in the judicious indication of colonoscopy in this subgroup of patients. It is relevant because SpA patients more frequently develop bowel inflammation than the general population2 and microscopic bowel inflammation appears to be a prognostic marker in SpA.3-6 We recruited 65 patients with SpA, in the pre-COVID-19 era in Brazil (the study was finished in August of 2019), without known chronic gastrointestinal disease, the majority of whom were oligosymptomatic. The decision to exclude patients with overt IBD and other chronic gastrointestinal diseases was to assess if fcal could be used to identify SpA patients at risk of bowel inflammation. Therefore, we did not find it necessary to look for extraintestinal manifestations related to IBD, such as acute pancreatitis. The use of indices to quantify the inflammatory activity of IBD was also not applicable. Second, we agree that fcal is a useful biomarker of bowel inflammation. However, it has limited specificity because its values can be influenced by various factors including age, smoking status, medication, pregnancy, SpA involvement subtypes, and disease activity. The literature shows that the interpretation of the fcal's cut-offs must consider the patient's clinical context, so different values are accepted for specific situations.7 In our research, we adjusted the factors that were most studied and well described as confounders of fcal levels in previous studies. Although overweight and obesity are pointed out as potential factors that could interfere with fcal levels, they are based on small studies, with conflicting results and limited statistical power.8-10 More studies are necessary to evaluate the real association between fcal and BMI. We did evaluate possible associations between gender, age, smoking status, SpA duration in years, and fcal levels, but none showed statistical relevance in our study. Third, we mentioned in our article that the sample size was a major limitation that may have impaired some evaluations and conclusions, especially those related to SpA treatment and fcal levels, and bowel inflammation. The fact that the research could not manifest a temporal relationship between bowel inflammation and fcal levels is an inherent limitation related to the cross-sectional design, not a bias of the study itself. Finally, we agree that implementing stratification of fcal levels could mitigate doubts about overestimated fcal levels in some samples. Our study group intends to increase the sample size and also follow up those patients who had high fcal levels in our research in order to evaluate outcomes related to SpA and bowel inflammation.
No takes yet. Share an insight, caveat, or question.
Campos et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: